1. Search Result
Search Result
Results for "

Mct4 Inhibitors

" in MCE Product Catalog:
Cat. No. Product Name Target Research Areas
  • HY-132301

    Monocarboxylate Transporter Cancer
    MCT4-IN-1 is an orally active and selective monocarboxylate transporter 4 (MCT4/SLC16A3) inhibitor with an IC50 of 77 nM and a Ki of 11 nM. MCT4-IN-1 targets to the cytosolic domain of MCT4. MCT4-IN-1 results in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells. MCT4-IN-1 has the potential for MCT4 transporter inhibition research.
  • HY-N4115

    Su 3118

    Monocarboxylate Transporter Cancer Cardiovascular Disease
    Syrosingopine (Su 3118) is a potent and dual inhibitor of MCT1 and MCT4 with 60-fold higher potency on MCT4. Syrosingopine (Su 3118) prevents lactate and H+ efflux. Syrosingopine (Su 3118) is an anti-hypertensive drug with oral activity. Syrosingopine (Su 3118) combined with metformin has the potential for research cancer diseases.
  • HY-139665

    Monocarboxylate Transporter Cardiovascular Disease
    VB124 is an orally active, potent, and selective MCT4 inhibitor. VB124 can specifically inhibit lactate efflux with IC50s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1. VB124 can be used for the research of cardiac hypertrophy, heart failure, and metabolism.
  • HY-D0067

    DEAC; Coumarin D 1421; D 1421

    Monocarboxylate Transporter Cancer
    7ACC1(DEAC; Coumarin D 1421; D 1421) selectively interfere with lactate fluxes in the lactate-rich tumor microenvironment; inhibits lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters.
  • HY-122312

    Monocarboxylate Transporter Cancer
    BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity.